Table 2– Forced expiratory volume in 1 s standardised area under the curve from 0–4 h on day 1 and week 6

Treatment ( randomised patients n)	Patients in the analysis model n	Baseline	Treatment	Comparison	Treatment difference
		Mean±se	LSM±se		LSM±se	95% CI	p-value
Day 1
All patients
QVA149 (n=223)	220	1.32±0.03	1.56±0.01	QVA149 versus placebo	0.21±0.01	0.19–0.23	<0.001
				QVA149 versus tiotropium	0.07±0.01	0.05–0.09	<0.001
Tiotropium (n=220)	219	1.33±0.03	1.50±0.01	Tiotropium versus placebo	0.14±0.01	0.13–0.16	<0.001
Placebo (n=218)	217	1.33±0.03	1.35±0.01
Moderate COPD
QVA149 (n=151)	148			QVA149 versus placebo	0.23±0.01	0.21–0.26	<0.001
				QVA149 versus tiotropium	0.07±0.01	0.05–0.10	<0.001
Tiotropium (n=149)	148			Tiotropium versus placebo	0.16±0.01	0.14–0.19	<0.001
Placebo (n=149)	148
Severe COPD
QVA149 (n=72)	72			QVA149 versus placebo	0.17±0.02	0.13–0.20	<0.001
				QVA149 versus tiotropium	0.06±0.02	0.03–0.10	<0.001
Tiotropium (n=71)	71			Tiotropium versus placebo	0.10±0.02	0.07–0.14	<0.001
Placebo (n=69)	69
Week 6
All patients
QVA149 (n=223)	205	1.33±0.03	1.64±0.01	QVA149 versus placebo	0.33±0.01	0.31–0.36	<0.001
				QVA149 versus tiotropium	0.11±0.01	0.08–0.13	<0.001
Tiotropium (n=220)	209	1.34±0.03	1.53±0.01	Tiotropium versus placebo	0.23±0.01	0.20–0.25	<0.001
Placebo (n=218)	206	1.35±0.03	1.30±0.01
Moderate COPD
QVA149 (n=151)	136			QVA149 versus placebo	0.37±0.02	0.34–0.40	<0.001
				QVA149 versus tiotropium	0.11±0.02	0.08–0.15	<0.001
Tiotropium (n=149)	142			Tiotropium versus placebo	0.26±0.02	0.23–0.29	<0.001
Placebo (n=149)	142
Severe COPD
QVA149 (n=72)	69			QVA149 versus placebo	0.25±0.02	0.21–0.30	<0.001
				QVA149 versus tiotropium	0.09±0.02	0.05–0.14	<0.001
Tiotropium (n=71)	67			Tiotropium versus placebo	0.16±0.02	0.12–0.21	<0.001
Placebo (n=69)	64

LSM: least squares mean; COPD: chronic obstructive pulmonary disease.